Skip to main content
OpenTrials
Recruiting

NCT Number: NCT03756870

Revascularization Versus Optimal Medical Therapy of Chronic Total Coronary Occlusions on Left Ventricular Ischemia Reduction

Rationale: Randomized trials could not yet establish favourable outcomes of CTO PCI on hard endpoints such as ejection fraction or mortality, when compared to optimal medical therapy. However, patients after CTO PCI appeared to be more frequently free of angina complaints, but the aetiology behind this is not fully understood. The investigators hypothesize that PCI of the CTO in patients preselected with an ischemic threshold (>12.5%) on cardiac imaging leads to a reduction of the ischemic burden and therefore an increased benefit on functional outcomes.

Objective: Primary objective is to determine whether PCI of the CTO will yield a higher reduction of ischemia assessed by exercise myocardial perfusion SPECT-CT from baseline to 6-month follow-up compared to a control group. Secondary objectives are 1) to evaluate the effect of PCI of the CTO on improvement in functional status, infarct size and left ventricular function from baseline to follow-up compared to the control group; 2) to study the association between ischemia reduction and functional outcome and left ventricular function; 3) to assess the influence of the collateral flow index on the ischemic burden (reduction), functional status, infarct size and left ventricular (contractile) function (hibernation).

Study design: open multicentre randomized trial

Study population: 2x24 patients eligible for CTO PCI

Intervention: CTO PCI

Primary endpoint: ischemic burden assessed with exercise myocardial perfusion SPECT-CT from baseline to 6 months follow-up.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Amsterdam UMC, location AMC

Amsterdam, 1105AZ, Netherlands

Location status: Recruiting

Location contact

Anna van Veelen, MD

CONTACT

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • A chronic total occlusion is present and target lesion. A CTO is required to meet the following characteristics:
  • A 100% luminal narrowing of the coronary artery without antegrade flow, i.e. Thrombolysis in Myocardial Infarction flow grade 0 or 1;
  • Older than 3 months, established with previous PCI or with angiographic characteristics;
  • Amenable to percutaneous revascularization.
  • Patient has a clinical indication to perform CTO PCI.
  • A SPECT is performed at baseline to assess ischemia and a cardiac magnetic resonance imaging (CMR) scan to assess viability, as part of routine patient care. Patients are deemed eligible for the randomized trial when they meet the ischemic threshold in the CTO territory.

The ischemic threshold is defined as:

  • >12.5% of ischemia;
  • With <50% transmural extent of infarction.
  • Subject agrees to undergo follow-up SPECT-CT at 6 months after initial inclusion
  • Subject is able to verbally confirm understanding and he/she provides written informed consent prior to any Clinical Investigation related procedure, as approved by the appropriate Ethics Committee.

Exclusion criteria

  • Subject is younger than 18 years of age;
  • Persistent or permanent atrial fibrillation;
  • Presence of a non-MRI compatible cardiac device, i.e. pacemaker or implantable cardioverter defibrillator;
  • Body weight > 250 kg;
  • Unable to exert, i.e. due to physical disability;
  • Any contraindication for SPECT or CMR, i.e. cerebrovascular clips, claustrophobia;
  • Known renal insufficiency (estimated Glomerular Filtration Rate [eGFR] <60 mL/min/1.73m2 or serum creatinine level of >2.5 mg/dL or subject on dialysis);
  • Hypersensitivity or allergy to contrast with inability to properly pre-hydrate;
  • Presence of a comorbid condition with a life expectancy of less than one year;
  • Participation in another trial;
  • Subject is belonging to a vulnerable population (per investigator's judgment, e.g., subordinate hospital staff) or is unable to read or write.

Treatment and study plan

Percutaneous Coronary Intervention (PCI)

Procedure

A percutaneous coronary intervention of the chronic total occlusion with a drug-eluting stent.

Primary outcomes

  1. Ischemia

    Time frame: 6 months follow-up

    Ischemic burden assessed with exercise myocardial perfusion SPECT-CT from baseline to 6 months follow-up.

Secondary outcomes

  1. Change in angina status assessed with the Seattle Angina Questionnaire.

    Time frame: 6 months, 1 year, 2 years, 3 years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years, 10 years

    5 Seattle Angina Questionnaire subscales (0-100), higher scores indicating better angina status.

  2. Quality of life assessed with the Minnesota Living with Heart Failure Questionnaire (MLHFQ)

    Time frame: 6 months, 1 year, 2 years, 3 years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years, 10 years

    MLHFQ scale (0-105), lower scores indicating better quality of life.

  3. The left ventricular ejection fraction assessed with cardiac magnetic resonance imaging

    Time frame: 6 months

Study contacts

Contact information is provided by the study sponsor or research team.

Ms. A. van Veelen, MD

CONTACT

[email protected]

+31205666405

Prof. J.P.S. Henriques, MD PhD

CONTACT

[email protected]

+31205666405

Sponsors and collaborators

Lead sponsor

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Other

Registry information

Official study title

REvascularization Versus Optimal Medical Therapy on Left Ventricular ISchemia Reduction: Exploring the Associations Between Ischemia, Functional Outcome and Collaterals in the Treatment of Chronic Total Occlusion Patients

Acronym: REVISE-CTO

Important dates

Study start
2019
Primary completion
2026
Study completion
2030
First posted
Nov 28, 2018
Registry last updated
Jul 6, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.